Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies

Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies

Systemic lupus erythematosus (SLE) and bullous pemphigoid (BP) are chronic autoimmune diseases in which B cells play an important pathogenic role in the different stages of the disease. B cell-targeted therapies have been suggested as a new rational approach for treating SLE. Rituximab (RTX), an ant...

Full description

Bibliographic Details
Main Authors: Luca Petricca, Maria Rita Gigante, Annamaria Paglionico, Stefano Costanzi, Gisella Vischini, Clara Di Mario, Valentina Varriano, Giacomo Tanti, Barbara Tolusso, Stefano Alivernini, Giuseppe Grandaliano, Gianfranco Ferraccioli, Elisa Gremese
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Medicine
Subjects:
lupus nephritis
bullous pemphigoid
belimumab
rituximab
sequential therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2020.553075/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2020.553075/full

Similar Items